Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A machine ...
The Brighterside of News on MSN8d
Cutting-edge AI diagnoses schizophrenia and bipolar disorders earlierSchizophrenia and bipolar disorder are severe mental illnesses that often disrupt daily life, affecting social interactions, ...
Late-onset schizophrenia is relatively rare. Further history may reveal prodromal symptoms that mimic ... as well as bipolar disorder, manic phase.
In fall 2024, xanomeline trospium chloride (XT) was approved by the U.S. Food and Drug Administration for the treatment of ...
Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline ...
The pivotal clinical phase 3 trial for the olanzapine Long-Acting Injectable (LAI) in schizophrenia (SOLARIS) has been completed, following the final visit of the last patient in the 48 weeks open ...
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE David Heuzé Head of Corporate and Financial Communications, and ESG [email protected] ...
As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia." ...
Ketamine can trigger symptoms similar to those of schizophrenia, but it isn’t known to cause the disorder itself. Ketamine is gaining attention for its potential to treat depression and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback